TABLE 2.
Summary of 20 NSCLC cases analyzed for fusion detection by cfRNA‐based assay
| Case # | Sex | Age | Stage | Tissue analysis | Metastasis | Treatment | Treatment at sample collection | Status at sample collection | Liquid fusion detection | Gene alteration cfDNA | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fusion | Method | 1st | 2nd | 3rd | cfRNA | cfDNA | ||||||||
| #1 | F | 30 | IVB | EML4‐ALK | NGS | Bo, Li | Alectinib | Chemo | ‐ | 1st | PD | EML4‐ALK | NA | NA |
| #2 | F | 85 | IVB | ALK | IHC | Bo, Ly | Alectinib | ‐ | ‐ | Pre | Naïve | ND | NA | NA |
| #3 | F | 55 | IVB | ALK | IHC | Bo, Li | Alectinib | Chemo | ‐ | 1st | PD | EML4‐ALK | EML4‐ALK |
TP53 G266E (9.07%) ALK I1171N (0.54%) |
|
TP53 G266E (9.07%) ALK I1171N (0.54%) | ||||||||||||||
| #4 | M | 53 | IVB | EZR‐ROS1 | NGS | Pa, Ly | Crizotinib | Chemo | ‐ | 1st | PD | EZR‐ROS1 | ND | TP53 E204* (0.14%) |
| 2nd | PR | ND | ND | ND | ||||||||||
| #5 | F | 36 | IIIC | CD74‐ROS1 | NGS | Ly | Crizotinib | ‐ | ‐ | Pre | Naïve | CD74‐ROS1 | ND | TP53 L145P (0.3%) |
| 1st | PR | ND | ND | ND | ||||||||||
| #6 | F | 36 | IVB | RET | NGS | Ly | Selpercatinib | ‐ | ‐ | Pre | Naïve | KIF5B‐RET | KIF5B‐RET | ND |
| 1st | PR | ND | ND | ND | ||||||||||
| #7 | M | 57 | IIIA | EML4‐ALK | RT‐PCR | Ly | Operation | Chemo | Alectinib | 3rd | PD | EML4‐ALK | ND | ND |
| #8 | F | 29 | IVB | ALK | NGS | Br | Alectinib | ‐ | ‐ | Pre | Naïve | EML4‐ALK | ND |
BRCA1 S1212P (0.56%) FBXW7 T536R (0.12%) |
| #9 | F | 70 | IVA | RET | NGS | Pl | Selpercatinib | ‐ | ‐ | Pre | Naïve | KIF5B‐RET | KIF5B‐RET | ND |
| #10 | M | 49 | IVA | ALK | NGS | Pl | Alectinib | ‐ | ‐ | Pre | Naïve | ND | ND | ND |
| #11 | M | 44 | IV | ALK | IHC | Br, Bo, Ly | Alectinib | Chemo | Lorlatinib | 3rd | PD | ND | ND | ND |
| #12 | F | 65 | IIB | EML4‐ALK | RT‐PCR | Ly | Operation | Alectinib | ‐ | 2nd | PR | ND | ND | ND |
| #13 | M | 61 | IIA | ALK | IHC | Ly | Operation | Alectinib | ‐ | 2nd | PR | ND | ND | AR G300A (1.89%) |
| #14 | F | 66 | IIIB | ALK | IHC | Ly | Chemo | Alectinib | ‐ | 2nd | CR | ND | NA | NA |
| 2nd | CR | ND | ND | TP53 V274A (0.18%) | ||||||||||
| #15 | M | 64 | IV | ALK | IHC | Br | Alectinib | Chemo | Lorlatinib | 3rd | PR | ND | NA | NA |
| 3rd | PR | ND | NA | NA | ||||||||||
| #16 | M | 58 | IVB | ALK | FISH | Br, Bo | Alectinib | Pembro | Lorlatinib | 3rd | SD | ND | NA | NA |
| 3rd | SD | ND | NA | NA | ||||||||||
| #17 | M | 78 | IV | ALK | FISH | Pl | Alectinib | Lorlatinib | Chemo | 3rd | PR | ND | NA | NA |
| 3rd | PR | ND | NA | NA | ||||||||||
| #18 | M | 63 | IVB | ALK | IHC | Br, Bo | Alectinib | ‐ | ‐ | 1st | PR | ND | NA | NA |
| 1st | PR | ND | ND | ND | ||||||||||
| #19 | F | 86 | IV | EZR‐ROS1 | RT‐PCR | Pl | Chemo | Pembro | Crizotinib | 3rd | PR | ND | NA | NA |
| 3rd | PR | ND | ND | ND | ||||||||||
| #20 | F | 84 | IVA | CD74‐ROS1 | RT‐PCR | Pl | Crizotinib | ‐ | ‐ | 1st | PR | ND | NA | NA |
| 1st | PR | ND | ND |
TP53 R213P (0.14%) RAF1 S26N (0.11%) ERBB2 (CN = 2.19) |
||||||||||
Variant allele frequencies detected with the cfDNA‐based assay are shown in parentheses. *, stop codon.
Abbreviations: Bo, bone; Br, brain; Chemo, cytotoxic chemotherapy; CN, copy number; FISH, fluorescence in situ hybridization; IHC, immunohistochemical; Li, liver; Ly, lymph node; NA, not analyzed; ND, not detected; NGS, next‐generation sequencing; Pa, pancreas; PD, progressive disease; Pl, pleura; PR, partial response; RT‐PCR, reverse‐transcription PCR; SD, stable disease.